Advisors Asset Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $86.3K | Sell |
4,803
-5,431
| -53% | -$103K | ﹤0.01% | 1256 |
|
|
2026
Q1 | $223K | Sell |
10,234
-761
| -7% | -$14.7K | ﹤0.01% | 1130 |
|
|
2025
Q4 | $237K | Sell |
10,995
-1,171
| -10% | -$24.7K | ﹤0.01% | 1100 |
|
|
2025
Q3 | $234K | Sell |
12,166
-378
| -3% | -$6.74K | ﹤0.01% | 1095 |
|
|
2025
Q2 | $215K | Sell |
12,544
-3,753
| -23% | -$160K | ﹤0.01% | 1110 |
|
|
2025
Q1 | $1.04M | Buy |
16,297
+4,728
| +41% | +$498K | 0.02% | 737 |
|
|
2024
Q4 | $1.41M | Sell |
11,569
-3,300
| -22% | -$404K | 0.03% | 649 |
|
|
2024
Q3 | $1.86M | Buy |
14,869
+43
| +0.3% | +$5.94K | 0.03% | 581 |
|
|
2024
Q2 | $2.34M | Buy |
14,826
+675
| +5% | +$86.7K | 0.05% | 494 |
|
|
2024
Q1 | $1.83M | Buy |
14,151
+736
| +5% | +$90.2K | 0.04% | 576 |
|
|
2023
Q4 | $1.29M | Sell |
13,415
-9,289
| -41% | -$891K | 0.03% | 656 |
|
|
2023
Q3 | $2.75M | Buy |
22,704
+1,335
| +6% | +$151K | 0.06% | 398 |
|
|
2023
Q2 | $2.45M | Buy |
21,369
+3,910
| +22% | +$504K | 0.05% | 450 |
|
|
2023
Q1 | $2.41M | Buy |
17,459
+675
| +4% | +$87.6K | 0.05% | 464 |
|
|
2022
Q4 | $2.17M | Buy |
16,784
+65
| +0.4% | +$7.53K | 0.04% | 477 |
|
|
2022
Q3 | $1.85M | Buy |
16,719
+5,998
| +56% | +$605K | 0.04% | 530 |
|
|
2022
Q2 | $804K | Buy |
+10,721
| New | +$789K | 0.02% | 815 |
|
|
2022
Q1 | – | Sell |
-23,780
| Closed | -$2.14M | – | 1130 |
|
|
2021
Q4 | $2.14M | Buy |
23,780
+229
| +1% | +$19.6K | 0.03% | 583 |
|
|
2021
Q3 | $2.18M | Sell |
23,551
-191
| -0.8% | -$14.7K | 0.03% | 567 |
|
|
2021
Q2 | $1.85M | Buy |
23,742
+3,296
| +16% | +$250K | 0.03% | 622 |
|
|
2021
Q1 | $1.52M | Buy |
20,446
+6,771
| +50% | +$625K | 0.02% | 683 |
|
|
2020
Q4 | $2.33M | Buy |
13,675
+5,133
| +60% | +$761K | 0.04% | 492 |
|
|
2020
Q3 | $1.2M | Buy |
8,542
+3,672
| +75% | +$558K | 0.02% | 653 |
|
|
2020
Q2 | $781K | Buy |
4,870
+3,481
| +251% | +$474K | 0.02% | 758 |
|
|
2020
Q1 | $136K | Sell |
1,389
-526
| -27% | -$60.1K | ﹤0.01% | 1179 |
|
|
2019
Q4 | $247K | Sell |
1,915
-1,960
| -51% | -$198K | ﹤0.01% | 1151 |
|
|
2019
Q3 | $292K | Buy |
3,875
+50
| +1% | +$5.91K | 0.01% | 1101 |
|
|
2019
Q2 | $581K | Buy |
3,825
+14
| +0.4% | +$1.7K | 0.01% | 960 |
|
|
2019
Q1 | $454K | Buy |
3,811
+338
| +10% | +$43.5K | 0.01% | 1008 |
|
|
2018
Q4 | $379K | Buy |
3,473
+470
| +16% | +$58.8K | 0.01% | 1046 |
|
|
2018
Q3 | $485K | Buy |
+3,003
| New | +$411K | 0.01% | 1066 |
|
Other funds holding SRPT
EAM
Advisors Asset Management's SRPT Position: Q2 2026 in Review
Advisors Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 53% in Q2 2026, selling an estimated $103K and leaving 4,803 shares worth $86.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1256.
Advisors Asset Management first reported a position in SRPT in Q3 2018 and has held it in 31 quarters since. The position peaked at $2.75M in Q3 2023. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Advisors Asset Management held 4,803 shares of Sarepta Therapeutics worth $86.3K as of Q2 2026.
- Advisors Asset Management sold 5,431 Sarepta Therapeutics shares in Q2 2026, an estimated $103K.
- Sarepta Therapeutics made up ﹤0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1256 holding.
- Advisors Asset Management first reported a position in Sarepta Therapeutics in Q3 2018 and has held it in 31 quarters since.
- Advisors Asset Management's Sarepta Therapeutics position peaked at $2.75M in Q3 2023.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.